p16 INK4a (DCS-50)Catalog number: P16002-L
Immunohistochemistry (frozen & paraffin)
The antibody is suitable to detect p16 in different tissues. Staining results may be cytoplasmatic or nuclear. Nuclear staining should be more specific. Human p16 INK4a (syn. CDKN2; MTS-1) protein is an inhibitor of Cyclin-Dependent-Kinases 4 and 6 (cdk4/cdk6). CDK4 is an important enzyme for the progression of the cell cycle during the G1-Phase. By it's inhibitory action p16 is an important regulator in the cell cycle. The gen encoding for p16 is deleted in many tumour cell lines. In adenocarcinoma of the cervix uteri usually p16 levels are increased. Endocervical p16-overexpression is mostly associated with "high risk" HPV-Typing. In other tumour types as squamous epithelial carcinoma in cervix uteri and head and neck carcinoma p16 expression usually is reduced.
Monoclonal antibody DCS-50 is produced after immunisation of Balb/c mice with the full length recombinant p16 INK4a protein of human origin.
Immunogen: Recombinant human p16 INK4a molecule
Protein A affinity purified antibody lyophilized from PBS pH7.4 with BSA and Na-Azide 0.09%.
Purification Method: Protein A affinity purification.
Secondary Reagents: We recommend the use of BIOLOGO's Universal Staining System DAB (Art. No. DA005) or AEC (Art.-No. AE005).
Concentration: Approximately 50 µg/ml after reconstitution in 1 ml distilled water
Species Reactivity: Human, other species not tested
IHC (C,P), IP
Incubation Time: 60 min at RT
Working Concentration: 1:10
Pre-Treatment: Pre-treatment with Unmasking Fluid C (Citrate Buffer, Art. No. DE000) or Unmasking Fluid G (Art. No. DE007) at 96-100 degree of Celsius is recommended for paraffin sections.
Positive Control: Colon carcinoma, HPV-pos. cervical carcinoma
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. It may contain hazardous ingredients. Please refer to the Safety Data Sheets (SDS) for additional information and proper handling procedures. Dispose product remainders according to local regulations.This datasheet is as accurate as reasonably achievable, but Exalpha Biologicals accepts no liability for any inaccuracies or omissions in this information.
1. Koh J., Enders G.H., Dynlacht B.D., and Harlow E. (1995) Tumour-derived p16 allels encoding proteins defective in cell cycle inhibition. Nature 375; 506-510. 2. Reed A.L., Califano J., Cairns P., Westra W.H., Jones R.M., et al. (1996) High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation of head and neck squamous cell carcinoma. Cancer Res. 56(16); 3630-3633. 3. Geradts J., Hruban R.H., Schütte M., Kern S.E., and Maynard R. (2000) Immunohistochemical p16INK4a analysis of archival tumors with deletion, hypermethylation, or mutation of the CDKN2/MTS1 gene. A comparison of four commercial antibodies. Appl. Immun 4. Negri G., Egarter-Vigl E., Kasal A., Romano F., Haitel A., Mian C. (2003) p16INK4a is a useful marker for the diagnosis of adenocarcinoma of the cervix uteri and its precursors: an immunohistochemical study with immunocytochemical correlations. Am J. S 5. Kotaro R. Shibata,Tomoki Aoyama,Yasuko Shima et al. (2007) Expression of the p16INK4A Gene Is Associated Closely with Senescence of Human Mesenchymal Stem Cells and Is Potentially Silenced by DNA Methylation During In Vitro Expansion Stemm Cells vol. 9; 2371–2382.
Database Name: UniProt
Accession Number: P42771 (CD2A1_HUMAN)
Species Accession: Human